biologic

Trutakna

atacicept-vymj

Loss of exclusivityJuly 2038projected — 12-year biologic exclusivity estimate
CompanyVera Therapeutics, Inc.

Drug detail

Brand nameTrutakna
Active ingredientatacicept-vymj
Strength150MG/ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalJuly 2026
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.